



Corporate Profile

ICAV/CITAV was incorporated in January 2006 as a company without share capital under part II of the Canada Corporations Act (file number 433450-7) and operates as a not-for-profit drug discovery and development company. The CCRA Business number is 81327 9478.

Directors: Jeremy Carver, CEO/CSO, ICAV; Michel Chrétien, Director of International Partnerships, ICAV, Philippe Douste-Blazy, Under-Secretary General, United Nations, Brian Gray, Lawyer, Ogilvy Renault LLP; Patrick Michaud (Chair), Managing Director, Templar Associates Inc., Bonnie M. Patterson, President and CEO, Council of Ontario Universities, Andy Mitchell, President and CEO, Greater Peterborough Area Economic Development Corporation

Special Advisor to the CEO: Hon. Donald Johnston, former Secretary-General of the OECD.

International Research Advisory Board: Sir John Skehel (Chair), Peter Doherty, Donald Low, Jeremy Carver, Michel Chrétien, Nabil Seidah.

Management Team: Jeremy Carver, President, CEO & CSO; Michel Chrétien, Director of International Partnerships; Dale Cumming, Director of Scientific Evaluation; Denis Ferkany, Director of Corporate Strategy; Christian D. Frayssignes, Business Development; Wendy Hill, Director of Clinical Development; Linda Kurdydyk, Director of Intellectual Property; Nathaniel Lewis, Director of Communications; Oyekanmi Nash, Regional Director for Africa; Rajan Shah, Director of Applied Chemistry.

International Steering Committee: Dr. Ralf Altmeyer, CEO, CombinatoRx, Singapore; Dr. Bruno Canard, Research Director, Research Director, VIZIER/AFMB, Marseille, France, Dr. Jeremy Carver, CEO, ICAV, Canada; Dr. Michel Chrétien, International Partnerships, ICAV, Canada; Dr. Erik de Clercq, Faculty of Medicine, Rega Institute, Leuven, Belgium; Dr. George Fu Gao, Senior Scientist, Institute of Microbiology, CAS, Beijing, China; Dr. Rolf Hilgenfeld, Director, Institute of Biochemistry, University of Lübeck, Germany; Dr. Hans-Dieter Klenk, Institute of Virology, University of Marburg, Germany; Dr. Albert Osterhaus, Head, Department of Virology, Erasmus University, Netherlands; Sir John Skehel, Former Director of the MRC-NIMR, Mill Hill, UK; Professor Oyewale Tomori, Vice Chancellor, Redeemer's University, Nigeria; Dr. Noël Tordo, Institut Pasteur, France; Dr. Igor Tvaroska, Director, Institute of Chemistry, Slovak Academy of Sciences, Slovakia; Dr. Mark von Itzstein, Director of the Institute for Glycomics, Griffith University, Australia; Dr. Andrew Wang, Director, Institute of Biological Chemistry, Academia Sinica, Taiwan.

Technical Review Committee: Theo Anucha, Formulation and Manufacturing; Isobel Ralston, Pre-clinical Development; Miklos Shultz, Clinical Design and Biostatistics; Saul Ship, Market Analysis; Anne Tomalin, Regulatory Affairs.

Foundation on Anti-Virals (FAV) Board of Directors: Jean-Claude Baumgarten, President, World Travel and Tourism Council; Jocelyn Beaudoin, President, FAV; Jeremy Carver, CEO/CSO, ICAV; Michel Chrétien, Director of International Partnerships, ICAV; Peter Harbison, Managing Director, Centre for Asia Pacific



Aviation; David Hill, Senior Partner, Perley-Robertson, Hill & McDougall LLP; Pierre Jeannot, Director-General Emeritus, IATA; Urban Joseph, Vice-Chairman (retired), TD Canada Trust; Pierre McCann, CIBC; The Honourable Michael Meighen, Senator, Canada; Alain Mérieux, Chairman, La Fondation Mérieux.

Foundation on Anti-Virals Honorary Patrons: The Right Honorable Jean Chrétien, former Prime Minister of Canada; Jacques Chirac, former President of France.